Inquiry Basket
Loading ......
Vitamin D is an essential fat-soluble nutrient traditionally associated with calcium metabolism and bone health. However, its biological role extends considerably beyond the skeletal system. Serum 25-hydroxyvitamin D [25(OH)D] is the principal circulating biomarker used to evaluate vitamin D status, while its active metabolite, 1,25-dihydroxyvitamin D [1,25(OH)2D], participates in a wide range of immune-regulatory processes. The respiratory tract is continuously exposed to viruses, bacteria, allergens, and environmental pollutants, making the integrity of its mucosal immune system essential for maintaining respiratory health. Increasing evidence suggests that vitamin D signaling contributes to this defense network by supporting epithelial barrier function, regulating antimicrobial peptides, and coordinating innate and adaptive immune responses. Understanding the relationship between 25(OH)D and respiratory mucosal immunity may therefore provide useful insights into respiratory infection susceptibility and the potential role of vitamin D status in immune health.
A growing body of epidemiological research has identified an association between lower serum 25(OH)D concentrations and a higher likelihood of respiratory infections. Population-based studies have generally reported that individuals with lower vitamin D status are more likely to experience upper respiratory tract infections than those with higher circulating 25(OH)D concentrations. This relationship has remained observable in several analyses after accounting for demographic and clinical factors. The association appears particularly relevant in people with underlying respiratory conditions. Studies involving individuals with asthma or chronic obstructive pulmonary disease (COPD) have reported links between low vitamin D status and greater respiratory morbidity or susceptibility to infection. These findings suggest that vitamin D status may interact with existing abnormalities in airway inflammation, epithelial barrier function, and immune regulation.
Pediatric studies provide similar observations. Children experiencing recurrent respiratory infections have frequently been found to have lower 25(OH)D concentrations and, in some studies, altered immunoglobulin profiles. Clinical investigations have further suggested that vitamin D supplementation may improve certain clinical outcomes and reduce the frequency of recurrent respiratory infections in children with inadequate vitamin D status. Nevertheless, observational associations cannot establish that low 25(OH)D directly causes respiratory infections, and supplementation studies have produced variable results across different populations.
The respiratory epithelium represents one of the body's most important physical barriers against inhaled pathogens. Tight junctions between epithelial cells, mucus production, mucociliary clearance, and continuous epithelial repair work together to prevent microorganisms from penetrating deeper tissues. Vitamin D signaling appears to contribute to the maintenance of this barrier. Respiratory epithelial cells contain components of the vitamin D metabolic and signaling pathways, allowing local vitamin D activity to influence cellular responses. Through the vitamin D receptor, active vitamin D can regulate genes involved in epithelial differentiation, barrier integrity, and tissue repair. A well-maintained epithelial barrier limits pathogen access while reducing unnecessary exposure of underlying immune cells to environmental stimuli. This may be particularly important during respiratory infections, when epithelial damage can amplify inflammation and increase tissue susceptibility to secondary injury.
Another important mechanism involves antimicrobial peptides. Active vitamin D signaling can promote the expression of antimicrobial molecules, particularly cathelicidin and its human form LL-37. These peptides form part of the respiratory tract's first-line defense system. They can interact with bacteria and viruses, influence microbial membrane integrity, and contribute to local immune signaling. Vitamin D-dependent regulation of antimicrobial peptides therefore provides a biological explanation for why adequate vitamin D signaling may support early mucosal defense. Vitamin D may also influence proteins involved in epithelial adhesion and barrier organization. The combined effects on antimicrobial activity and epithelial integrity suggest that vitamin D can support the respiratory mucosa as both a physical and immunological barrier.
Respiratory mucosal immunity depends heavily on innate immune mechanisms. Airway epithelial cells, macrophages, monocytes, dendritic cells, and other immune populations rapidly recognize microbial signals and initiate responses against invading pathogens. Vitamin D can influence the activity of monocytes and macrophages and regulate antimicrobial responses following pathogen recognition. Rather than simply stimulating immunity, vitamin D appears to function primarily as an immune modulator. It can support antimicrobial defense while helping regulate excessive inflammatory signaling. This balance is particularly important in the respiratory system. An inadequate immune response may allow pathogens to persist, whereas uncontrolled inflammation can damage epithelial tissue and impair normal airway function. Vitamin D signaling may contribute to maintaining an appropriate balance between pathogen clearance and inflammatory control.
The effects of vitamin D extend beyond innate immune defense. Vitamin D receptor signaling can influence T-cell differentiation, cytokine production, antigen-presenting cell activity, and other processes involved in adaptive immunity. Vitamin D may also affect B-cell function and immunoglobulin production. This provides a potential explanation for observations in some pediatric studies in which correction of low vitamin D status was accompanied by changes in IgG, IgA, and IgM levels. However, these effects should not be interpreted as evidence that increasing vitamin D indefinitely will produce progressively stronger immunity. Immune regulation is complex, and vitamin D appears to influence the balance and quality of immune responses rather than simply increasing overall immune activity.
Experimental research has provided additional evidence for a potential role of vitamin D in antiviral defense. Laboratory studies using respiratory epithelial cell models have suggested that vitamin D exposure can increase cellular resistance to certain respiratory viruses, including rhinovirus. Researchers have also observed changes in the expression of host molecules involved in viral attachment and cellular entry. For example, vitamin D-related signaling has been investigated in relation to molecules such as intercellular adhesion molecule-1 (ICAM-1) and platelet-activating factor receptor (PAFR), which can participate in respiratory viral interactions with host cells. These findings suggest that vitamin D may influence the susceptibility of airway epithelial cells to viral infection at the cellular level. However, laboratory observations should not be interpreted as direct evidence of clinical protection. Concentrations, exposure conditions, cell models, and host immune interactions in experimental systems may differ substantially from those encountered in humans.
Clinical intervention studies have produced encouraging but heterogeneous findings. Several investigations have suggested that vitamin D supplementation may reduce the risk or severity of certain respiratory infections, particularly among individuals who begin with relatively low vitamin D status. Some pediatric studies have reported fewer recurrent respiratory infections and improvements in selected immune markers following vitamin D supplementation. Other research has explored potential benefits in influenza, asthma exacerbations, and acute respiratory infections. Together, these findings support the hypothesis that correcting inadequate vitamin D status may contribute to better respiratory immune function in selected populations. At the same time, clinical trials have not produced completely consistent results. Differences in baseline 25(OH)D concentrations, age, underlying diseases, supplementation schedules, adherence, season, nutritional status, and definitions of respiratory outcomes can all influence study findings. For this reason, vitamin D should not be regarded as a universal preventive or therapeutic treatment for respiratory infections. Its potential value is more appropriately considered within an individualized approach to nutritional and respiratory health.
Serum 25(OH)D is widely used as the primary laboratory marker for evaluating vitamin D status because it reflects circulating vitamin D availability more effectively than the active metabolite 1,25(OH)2D for routine nutritional assessment. Reliable measurement of 25(OH)D can help identify individuals with inadequate vitamin D status when testing is clinically appropriate. Interpretation should consider the laboratory method, assay characteristics, clinical context, and applicable guideline thresholds rather than relying on a single value without context. For people with recurrent respiratory infections or chronic respiratory disorders, evaluating vitamin D status may provide useful information when deficiency is suspected or when other clinical factors support testing. However, vitamin D assessment should complement rather than replace established respiratory health strategies, including vaccination, appropriate infection prevention, smoking avoidance, and evidence-based management of asthma, COPD, and other respiratory conditions.
The biological connection between vitamin D and respiratory mucosal immunity is supported by multiple lines of evidence. Experimental studies demonstrate that vitamin D signaling can influence epithelial barrier function, antimicrobial peptides, innate immune cells, and adaptive immune responses. Observational research also consistently suggests that lower 25(OH)D status is associated with greater respiratory infection susceptibility in certain populations. The more difficult question is determining how strongly these mechanisms translate into clinical benefit. Some supplementation trials report meaningful reductions in respiratory infections, whereas others find limited or inconsistent effects. This difference highlights the importance of baseline vitamin D status and individual biological characteristics. Future research should therefore move beyond the question of whether vitamin D is beneficial in general. Greater attention is needed to identify which populations are most likely to benefit, what level of vitamin D status is clinically meaningful for respiratory immunity, and whether supplementation strategies should differ according to age, disease status, season, or baseline deficiency.
25-OH vitamin D represents an important link between nutritional status and respiratory immune function. Through conversion into active vitamin D metabolites and signaling through the vitamin D receptor, the vitamin D pathway can influence several components of respiratory mucosal defense, including epithelial barrier integrity, antimicrobial peptide production, innate immune activity, and adaptive immune regulation. A broad range of studies has associated lower 25(OH)D status with increased susceptibility to respiratory infections, particularly in certain vulnerable populations such as children with recurrent infections and individuals with chronic respiratory diseases. Experimental research further provides plausible mechanisms through which vitamin D may strengthen epithelial and antimicrobial defenses.
However, the available evidence does not support treating vitamin D as a stand-alone solution for respiratory infections. The potential benefits of supplementation appear to depend on baseline vitamin D status and individual clinical circumstances, and clinical trial results remain heterogeneous. Reliable 25(OH)D assessment when clinically indicated, appropriate correction of deficiency, and continued use of established respiratory prevention and treatment strategies represent a more evidence-based approach. As research continues to clarify the relationship between vitamin D metabolism and mucosal immunity, 25(OH)D may become increasingly relevant to personalized strategies for maintaining respiratory immune health.
25-OH vitamin D is the primary circulating marker of vitamin D status, while its active metabolite, 1,25(OH)2D, can influence respiratory immune function. Vitamin D signaling may support epithelial barrier integrity, promote antimicrobial peptide production, and regulate innate and adaptive immune responses.
Research generally suggests an association between lower 25(OH)D status and increased susceptibility to respiratory infections, particularly in some vulnerable populations. However, this relationship does not by itself prove that vitamin D deficiency directly causes respiratory infections.
Vitamin D signaling through the vitamin D receptor can influence genes involved in epithelial integrity, tight-junction function, cellular repair, and antimicrobial defense. These effects may help maintain the respiratory mucosa as an effective barrier against inhaled pathogens.
Some clinical studies suggest that vitamin D supplementation may reduce respiratory infection risk, especially among people with inadequate vitamin D status. However, results across clinical trials are not completely consistent, so supplementation should not be considered a substitute for vaccination or standard respiratory disease prevention and treatment.
Yes. Serum 25(OH)D is the standard biomarker commonly used to assess vitamin D status. When testing is clinically appropriate, results can help identify inadequate vitamin D status and inform individualized supplementation decisions.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit 0 2 | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
